Gyeonggi-do, South Korea

Jiyoong Chun

This inventor holds 1 USPTO granted patent. Top assignee: Qurient Co., Ltd.. Active years: 2026.


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jiyoong Chun: Innovator in Topical Anti-Inflammatory Treatments

Introduction

Jiyoong Chun is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in developing innovative treatments for inflammation. His work is characterized by a focus on topical applications that aim to improve patient outcomes.

Latest Patents

Jiyoong Chun holds 1 patent for a topical anti-inflammatory pharmaceutical composition comprising Zileuton. This invention relates to a formulation that not only provides anti-inflammatory benefits but also outlines methods for preparing such a composition. The potential applications of this invention could greatly enhance the treatment options available for patients suffering from inflammatory conditions.

Career Highlights

Chun is currently associated with Qurient Co., Ltd., a company dedicated to advancing pharmaceutical innovations. His role at Qurient has allowed him to focus on research and development, contributing to the company's mission of delivering effective therapeutic solutions.

Collaborations

Throughout his career, Jiyoong Chun has collaborated with talented individuals such as Kiyean Nam and Jaeseung Kim. These partnerships have fostered a creative environment that encourages the exchange of ideas and expertise, ultimately leading to groundbreaking advancements in their field.

Conclusion

Jiyoong Chun's work in developing a topical anti-inflammatory pharmaceutical composition demonstrates his commitment to innovation in healthcare. His contributions are poised to make a significant impact on the treatment of inflammatory conditions, showcasing the importance of research and collaboration in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…